165 related articles for article (PubMed ID: 36346546)
1. Atomoxetine Decreases Mitochondrial Biogenesis, Fission and Fusion In Human Neuron-like Cells But Does Not Alter Antioxidant Defences.
Carreón-Trujillo S; Vázquez-González D; Corona JC
Cell Biochem Biophys; 2023 Mar; 81(1):105-115. PubMed ID: 36346546
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine produces oxidative stress and alters mitochondrial function in human neuron-like cells.
Corona JC; Carreón-Trujillo S; González-Pérez R; Gómez-Bautista D; Vázquez-González D; Salazar-García M
Sci Rep; 2019 Sep; 9(1):13011. PubMed ID: 31506604
[TBL] [Abstract][Full Text] [Related]
3. The Interaction of Mitochondrial Biogenesis and Fission/Fusion Mediated by PGC-1α Regulates Rotenone-Induced Dopaminergic Neurotoxicity.
Peng K; Yang L; Wang J; Ye F; Dan G; Zhao Y; Cai Y; Cui Z; Ao L; Liu J; Zou Z; Sai Y; Cao J
Mol Neurobiol; 2017 Jul; 54(5):3783-3797. PubMed ID: 27271125
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
Walker DJ; Mason O; Clemow DB; Day KA
Postgrad Med; 2015; 127(7):686-701. PubMed ID: 26343377
[TBL] [Abstract][Full Text] [Related]
5. Synergy in Disruption of Mitochondrial Dynamics by Aβ (1-42) and Glia Maturation Factor (GMF) in SH-SY5Y Cells Is Mediated Through Alterations in Fission and Fusion Proteins.
Ahmed ME; Selvakumar GP; Kempuraj D; Thangavel R; Mentor S; Dubova I; Raikwar SP; Zaheer S; Iyer S; Zaheer A
Mol Neurobiol; 2019 Oct; 56(10):6964-6975. PubMed ID: 30949973
[TBL] [Abstract][Full Text] [Related]
6. Cocoa beans improve mitochondrial biogenesis via PPARγ/PGC1α dependent signalling pathway in MPP
Chidambaram SB; Bhat A; Ray B; Sugumar M; Muthukumar SP; Manivasagam T; Justin Thenmozhi A; Essa MM; Guillemin GJ; Sakharkar MK
Nutr Neurosci; 2020 Jun; 23(6):471-480. PubMed ID: 30207204
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial division inhibitor 1 reduces dynamin-related protein 1 and mitochondrial fission activity.
Manczak M; Kandimalla R; Yin X; Reddy PH
Hum Mol Genet; 2019 Jan; 28(2):177-199. PubMed ID: 30239719
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine Reestablishes Long Term Potentiation in a Mouse Model of Attention Deficit/Hyperactivity Disorder.
Piña R; Rozas C; Contreras D; Hardy P; Ugarte G; Zeise ML; Rojas P; Morales B
Neuroscience; 2020 Jul; 439():268-274. PubMed ID: 31809728
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Dittmann RW; Cardo E; Nagy P; Anderson CS; Bloomfield R; Caballero B; Higgins N; Hodgkins P; Lyne A; Civil R; Coghill D
CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
[TBL] [Abstract][Full Text] [Related]
11. Investigation of serum and brain superoxide dismutase levels depending on atomoxetine used in attention-deficit/hyperactivity disorder treatment: A combination of in vivo and molecular docking studies.
Gür F; Gür B; Erkayman B; Halıcı Z; Karakoç A
Bioorg Chem; 2020 Dec; 105():104435. PubMed ID: 33161254
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
[TBL] [Abstract][Full Text] [Related]
13. Dietary supplementation with acetyl-l-carnitine counteracts age-related alterations of mitochondrial biogenesis, dynamics and antioxidant defenses in brain of old rats.
Nicassio L; Fracasso F; Sirago G; Musicco C; Picca A; Marzetti E; Calvani R; Cantatore P; Gadaleta MN; Pesce V
Exp Gerontol; 2017 Nov; 98():99-109. PubMed ID: 28807823
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
[TBL] [Abstract][Full Text] [Related]
15. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD.
Ding YS; Naganawa M; Gallezot JD; Nabulsi N; Lin SF; Ropchan J; Weinzimmer D; McCarthy TJ; Carson RE; Huang Y; Laruelle M
Neuroimage; 2014 Feb; 86():164-71. PubMed ID: 23933039
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
Sikirica V; Findling RL; Signorovitch J; Erder MH; Dammerman R; Hodgkins P; Lu M; Xie J; Wu EQ
CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.
Clemow DB; Nyhuis AW; Robinson RL
CNS Neurosci Ther; 2016 Dec; 22(12):970-978. PubMed ID: 27476490
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study.
Smith T; Aman MG; Arnold LE; Silverman LB; Lecavalier L; Hollway J; Tumuluru R; Hyman SL; Buchan-Page KA; Hellings J; Rice RR; Brown NV; Pan X; Handen BL
J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):868-876.e2. PubMed ID: 27663942
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
